Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co IncfiledCriticalMerck & Co Inc
Priority to CS83235ApriorityCriticalpatent/CS233743B2/cs
Publication of CS233718B2publicationCriticalpatent/CS233718B2/cs
Způsob přípravy 6(R)-[2-[8(SH2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl- -1,2,3,4,4a(S),5,6,7,8,8a(S)-dekahydronaftyl-1(S)]ethyl]-4(R)-hydroxy- -3,4,5,6,-tetrahydro-2H-pyran-2-onu
6(r)-(2-(8'-acyloxy-2'-methyl-6'-methyl (or hydrogen)-polyhydronaphthyl-1')-ethyl)-4(r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-ones, the hydroxy acid form of said pyranones, the pharmaceutically acceptable salts of said hydroxy acids, and the lower alkyl, and phenyl, dimethylamino or acetylamino substituted lower alkyl esters of said hydroxy acid, processes for preparing the same, and a pharmaceutical antihypercholesterolemic composition containing the same
Hydrogenation products of mevinolin and dihydromevinolin, a process for preparing the same and an antihypercholesterolemic pharmaceutical composition containing the same
6(R)-(2-(8(S) (2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-decahydronaphthyl-1(S))ethyl)-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one, process for preparing and pharmaceutical composition containing the same